Why Lineage Cell Therapeutics Stock Is Soaring Today
Shares of Lineage Cell Therapeutics (NYSEMKT: LCTX) were soaring by 19.4% as of 12:01 p.m. EDT on Tuesday. The big gain came after the company announced positive news from a phase 1/2a study evaluating OpRegen in treating dry age-related macular degeneration (AMD).
Lineage Cell Therapeutics reported it observed restoration of retinal tissue in two additional patients in its study of OpRegen. The company reported its first case of retinal restoration last year. CEO Brian Culley said, "To our knowledge, these three patients represent the only examples of an experimental treatment for dry AMD demonstrating a reduction, rather than attenuating further expansion, of an area of atrophy in humans."
Image source: Getty Images.
Source Fool.com
